BACKGROUND: There is interest in different treatment strategies, including deintensification in good prognosis @entity1082 -positive (HPV(+)) @entity957 (SCC). We reviewed our experience with weekly @entity900 in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. METHODS: Data from @entity1 with low-risk HPV(+) oropharyngeal SCC treated with weekly @entity900 (40 mg/m(2) ) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1-2N1, T4 or N3 disease, or N2b to N2c disease in @entity1 with >10 pack-year smoking history. RESULTS: Of 31 @entity1 , the median age was 56 years (range, 41-69 years). All @entity1 completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of @entity900 . Grade 3 @entity33 occurred in 22 @entity1 (71%) and grade 3 @entity1398 in 6 @entity1 (19%). No @entity1 required enteral feeding at 12 months. The median follow-up was 30 months (range, 21-57 months) with no recurrences or @entity204 . CONCLUSION: Concurrent weekly @entity900 is relatively well-tolerated and associated with excellent disease control in low-risk, locoregionally advanced HPV(+) oropharyngeal SCC.    2015 Wiley Periodicals, Inc. Head Neck 38: E1117-E1121, 2016.

Weekly @entity900 and radiotherapy for low risk, locoregionally advanced XXXX -positive @entity957 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity957 :: ('MESH:D002294', 'Disease') :: ['oropharyngeal squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['febrile neutropenia'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity1082 :: (10566,Species) :: ['human papillomavirus']
